HuGE Literature Finder
Records
1
-
30
| A large-scale prospective concordance study of plasma- and tissue-based next-generation targeted sequencing for advanced non-small cell lung cancer (LC-SCRUM-Liquid). Clinical cancer research : an official journal of the American Association for Cancer Research 2022 Oct . Sugimoto Akira, Matsumoto Shingo, Udagawa Hibiki, Itotani Ryo, Usui Yuko, Umemura Shigeki, Nishino Kazumi, Nakachi Ichiro, Kuyama Shoichi, Daga Haruko, Hara Satoshi, Miyamoto Shingo, Kato Terufumi, Sakakibara-Konishi Jun, Tabata Eriko, Nakagawa Taku, Kawaguchi Tomoya, Sakai Tetsuya, Shibata Yuji, Izumi Hiroki, Nosaki Kaname, Zenke Yoshitaka, Yoh Kiyotaka, Goto Koic |
| Efficacy and potential resistance mechanisms of afatinib in advanced non-small cell lung cancer patients with EGFR G719X/L861Q/S768I. Cancer 2022 Sep . Pang Lan-Lan, Gan Jia-Di, Tan Jia-Rong, Huang Yi-Hua, Liao Jun, Liang Wei-Ting, Deng Peng-Bo, Fang Wen-Fe |
| Genotyping of cerebrospinal fluid in lung cancer patients with leptomeningeal metastasis. Thoracic cancer 2022 Sep 13 (18): 2574-2583. Nie Naifu, Zhou Haodong, Zhang Kejun, Liu Lan, Luo Nuo, Wang Renyuan, Li Xin, Zhu Mengxiao, Hu Chen, Wang Yubo, Liu Zhulin, Li Li, He Yo |
| Results from the IMpower132 China cohort: Atezolizumab plus platinum-based chemotherapy in advanced non-small cell lung cancer. Cancer medicine 2022 Sep . Lu Shun, Fang Jian, Wang Ziping, Fan Yun, Liu Yunpeng, He Jianxing, Zhou Jianying, Hu Jie, Xia Jinjing, Liu Wenxin, Shi Jane, Yi Jing, Cao Lej |
| Analysis of actionable genetic alterations in lung carcinoma from the VA National Precision Oncology Program. Seminars in oncology 2022 Jul . Jalal Shadia I, Guo Aixia, Ahmed Sara, Kelley Michael |
| Determination of Osimertinib, Aumolertinib, and Furmonertinib in Human Plasma for Therapeutic Drug Monitoring by UPLC-MS/MS. Molecules (Basel, Switzerland) 2022 Jul 27 (14): . Li Ying, Meng Lu, Ma Yinling, Li Yajing, Xing Xiaoqing, Guo Caihui, Dong Zhanj |
| A lung adenocarcinoma patient with co-mutations of MET and EGFR exon20 insertion responded to crizotinib. BMC medical genomics 2022 Jun 15 (1): 141. Chen Yan, Jiang Bo, He Yuange, Zhang Chu, Zhou Wenjie, Fang Cheng, Gu Dejian, Zhang Minxia, Ji Mei, Shi Juntao, Yang X |
| Association of Driver Oncogene Variations With Outcomes in Patients With Locally Advanced Non-Small Cell Lung Cancer Treated With Chemoradiation and Consolidative Durvalumab. JAMA network open 2022 Jun 5 (6): e2215589. Liu Yufei, Zhang Zhe, Rinsurongkawong Waree, Gay Carl M, Le Xiuning, Ning Matthew S, Lewis Jeff, Rinsurongkawong Vadeerat, Lee J Jack, Roth Jack, Swisher Stephen, Gandhi Saumil, Lee Percy P, Gibbons Don L, Vaporciyan Ara A, Heymach John V, Zhang Jianjun, Lin Steven |
| Crizotinib in MET Exon 14-Mutated or MET-Amplified in Advanced Disease Non-Small Cell Lung Cancer - A Retrospective, Single Institution Experience. Oncology 2022 Jun . Shalata Walid, Yakobson Alexander, Weissmann Sarah, Oscar Elron, Iraqi Muhammed, Kian Waleed, Peled Nir, Agbarya Ab |
| Clinicopathologic and Genomic Landscape of Non-Small Cell Lung Cancer Brain Metastases. The oncologist 2022 May . Huang Richard S P, Harries Lukas, Decker Brennan, Hiemenz Matthew C, Murugesan Karthikeyan, Creeden James, Tolba Khaled, Stabile Laura P, Ramkissoon Shakti H, Burns Timothy F, Ross Jeffrey |
| Gene alternation of cerebrospinal fluid in patients with leptomeningeal metastases of lung adenocarcinoma using next-generation sequencing. BMC cancer 2022 May 22 (1): 580. Yang Hainan, Wen Lei, Pan Yingying, Shan Changguo, Hong Weiping, Wang Hui, Zhou Cheng, Cai Linbo, Zhou Caic |
| Genomic features of Chinese small cell lung cancer. BMC medical genomics 2022 May 15 (1): 117. Liu Jun, Zhao Zhuxiang, Wei Shuquan, Li Binkai, Zhao Ziw |
| Dynamic changes in the systemic immune-inflammation index predict the prognosis of EGFR-mutant lung adenocarcinoma patients receiving brain metastasis radiotherapy. BMC pulmonary medicine 2022 Mar 22 (1): 75. Wang Qi, Tan Xiaojing, Deng Guangchuan, Fu Shuai, Li Jianbin, Li Zhenxia |
| A novel defined m7G regulator signature to investigate the association between molecular characterization and clinical significance in lung adenocarcinoma. Frontiers in oncology 2022 12 897323. Dong Yi, Li Yingge, Yao Yi, Song Qib |
| Analytical and clinical validation of a custom 15-gene next-generation sequencing panel for the evaluation of circulating tumor DNA mutations in patients with advanced non-small-cell lung cancer. PloS one 2022 17 (10): e0276161. Chow Yock Ping, Zainul Abidin Norziha, Kow Ken Siong, Tho Lye Mun, Wong Chieh L |
| Biomarker Discovery and Outcomes for Comprehensive Cell-Free Circulating Tumor DNA Versus Standard-of-Care Tissue Testing in Advanced Non-Small-Cell Lung Cancer. JCO precision oncology 2022 1 5 93-102. Palmero Ramon, Taus Alvaro, Viteri Santiago, Majem Margarita, Carcereny Enric, Garde-Noguera Javier, Felip Enriqueta, Nadal Ernest, Malfettone Andrea, Sampayo Miguel, Riva François, Nagy Rebecca J, Lanman Richard B, Faull Iris, Dix Daniel, Karachaliou Niki, Rosell Rafa |
| Biomarker Testing in Older Patients Treated for an Advanced or Metastatic Non-Squamous Non-Small-Cell Lung Cancer: The French ESME Real-Life Multicenter Cohort Experience. Cancers 2022 1 14 (1): . Lamy Tina, Cabarrou Bastien, Planchard David, Quantin Xavier, Schneider Sophie, Bringuier Michael, Besse Benjamin, Girard Nicolas, Chouaid Christos, Filleron Thomas, Simon Gaëtane, Baldini Capuci |
| Clinical and CT patterns to predict EGFR mutation in patients with non-small cell lung cancer: A systematic literature review and meta-analysis. European journal of radiology open 2022 2 9 100400. Ortiz Andrés Felipe Herrera, Camacho Tatiana Cadavid, Vásquez Andrés Francisco, Del Castillo Herazo Valeria, Neira Juan Guillermo Arámbula, Yepes María Mónica, Camacho Eduard Cadav |
| Co-occurrence CDK4/6 amplification serves as biomarkers of de novo EGFR TKI resistance in sensitizing EGFR mutation non-small cell lung cancer. Scientific reports 2022 02 12 (1): 2167. Sitthideatphaiboon Piyada, Teerapakpinyo Chinachote, Korphaisarn Krittiya, Leelayuwatanakul Nophol, Pornpatrananrak Nopporn, Poungvarin Naravat, Chantranuwat Poonchavist, Shuangshoti Shanop, Aporntewan Chatchawit, Chintanapakdee Wariya, Sriuranpong Virote, Vinayanuwattikun Chani |
| Genomic landscape of lung cancer in the young. Frontiers in oncology 2022 12 910117. Ruiz Rossana, Galvez-Nino Marco, Roque Katia, Montes Jaime, Nuñez Maria, Raez Luis, Sánchez-Gambetta Sergio, Jaúregui Sandra, Viale Sandra, Smith Edward S, Pinto Joseph A, Mas Lu |
| PD-L1 Expression in Chinese Patients with Advanced Non-Small Cell Lung Cancer (NSCLC): A Multi-Center Retrospective Observational Study. Journal of Cancer 2022 1 12 (24): 7390-7398. Yang Xin, Jiang Lili, Jin Yan, Li Peng, Hou Yingyong, Yun Jingping, Wu Chunyan, Sun Wenyong, Fan Xiangshan, Kuang Dong, Wang Weiya, Ni Jinsong, Mao Anhua, Tang Wenmin, Liu Zhenhua, Wang Jiali, Xiao Suijun, Li Yuan, Lin Dongm |
| Treatment Response to Immunotherapy After Crizotinib Resistance in a Patient With Pulmonary Sarcomatoid Carcinoma Harboring MET Exon 14 Skipping Mutation: A Case Report. Clinical Medicine Insights. Oncology 2022 2 16 11795549211067185. Gu Ling, Wei Xiaoying, Zhang Zixiang, Heng W |
| Evaluation of MET Non-Exon-14 Mutations as Biomarkers for Immunotherapy Outcomes Across Multiple Cancer Types. International journal of radiation oncology, biology, physics 2021 Nov 111 (3S): e101. Li X, Wang |
| NF1-Mutant Cancer and Immune Checkpoint Inhibitors: A Large Database Analysis. International journal of radiation oncology, biology, physics 2021 Nov 111 (3S): e421. Li X, Yu J, Wang |
| Effect of mesenchymal-epithelial transition amplification on immune microenvironment and efficacy of immune checkpoint inhibitors in patients with non-small cell lung cancer. Annals of translational medicine 2021 Sep 9 (18): 1475. Su Shan, Lin Anqi, Luo Peng, Zou Jianjun, Huang Zhihao, Wang Xiaojun, Zeng Yunyun, Cen Wenchang, Zhang Xianlan, Huang Huiyi, Hu Jinxing, Zhang Ji |
| PD-L1 Expression and Comprehensive Molecular Profiling Predict Survival in Nonsmall Cell Lung Cancer: A Real-World Study of a Large Chinese Cohort. Clinical lung cancer 2021 Aug . Jin Yan, Xue Qianqian, Shen Xuxia, Zheng Qiang, Chen Haiquan, Zhou Xiaoyan, Li Yu |
| Genetic variations of rs6928 and rs5999521 of ERK2 were found to have correlation with the risk of brain metastasis in patients with lung adenocarcinoma. Translational cancer research 2021 May 10 (5): 2134-2143. Li Bo, Lv Zheng, Zhao Gang, Li Youqi, Qiu Xiaogua |
| Landscape and Clonal Dominance of Co-occurring Genomic Alterations in Non-Small-Cell Lung Cancer Harboring MET Exon 14 Skipping. JCO precision oncology 2021 12 5 . Le Xiuning, Hong Lingzhi, Hensel Chuck, Chen Rongrong, Kemp Haley, Coleman Niamh, Ciunci Christine A, Liu Stephen V, Negrao Marcelo V, Yen Jennifer, Xia Xuefeng, Scheuenpflug Juergen, Stroh Christopher, Juraeva Dilafruz, Tsao Anne, Hong David, Raymond Victoria, Paik Paul, Zhang Jianjun, Heymach John |
| Molecular characterization and clinical outcomes in EGFR-mutant de novo MET-overexpressed advanced non-small-cell lung cancer. ESMO open 2021 12 7 (1): 100347. Mi J, Huang Z, Zhang R, Zeng L, Xu Q, Yang H, Lizaso A, Tong F, Dong X, Yang N, Zhang |
| Molecular characterization of lung carcinomas: A study on diagnostic, predictive, and prognostic markers using immunohistochemical analysis at a Tertiary Care Center in Uttarakhand, India. Journal of carcinogenesis 2021 20 17. Rao Shalinee, Anthony Michael Leonard, Chowdhury Nilotpal, Kathrotia Rajesh, Mishra Mayank, Naithani Manisha, Sindhwani Girish, Singh Ne |
- Page last reviewed:Jul 25, 2022
- Page last updated:Jan 27, 2023
- Content source: